Galectin Therapeutics Statistics
Total Valuation
GALT has a market cap or net worth of $85.61 million. The enterprise value is $175.79 million.
Important Dates
The next estimated earnings date is Wednesday, May 14, 2025, before market open.
| Earnings Date | May 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
GALT has 63.18 million shares outstanding. The number of shares has increased by 3.57% in one year.
| Current Share Class | 63.18M |
| Shares Outstanding | 63.18M |
| Shares Change (YoY) | +3.57% |
| Shares Change (QoQ) | +0.75% |
| Owned by Insiders (%) | 20.58% |
| Owned by Institutions (%) | 15.98% |
| Float | 44.01M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | -0.82 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.49
| Current Ratio | 0.49 |
| Quick Ratio | 0.43 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -7.66 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -116.08% |
| Return on Invested Capital (ROIC) | -359.82% |
| Return on Capital Employed (ROCE) | 236.87% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$3.15M |
| Employee Count | 15 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -55.72% in the last 52 weeks. The beta is 0.79, so GALT's price volatility has been lower than the market average.
| Beta (5Y) | 0.79 |
| 52-Week Price Change | -55.72% |
| 50-Day Moving Average | 1.47 |
| 200-Day Moving Average | 2.04 |
| Relative Strength Index (RSI) | 45.52 |
| Average Volume (20 Days) | 218,236 |
Short Selling Information
The latest short interest is 7.89 million, so 12.49% of the outstanding shares have been sold short.
| Short Interest | 7.89M |
| Short Previous Month | 8.15M |
| Short % of Shares Out | 12.49% |
| Short % of Float | 17.93% |
| Short Ratio (days to cover) | 29.37 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -42.43M |
| Pretax Income | -44.65M |
| Net Income | -47.20M |
| EBITDA | n/a |
| EBIT | -42.43M |
| Earnings Per Share (EPS) | -$0.76 |
Full Income StatementBalance Sheet
The company has $15.12 million in cash and $106.25 million in debt, giving a net cash position of -$91.13 million or -$1.44 per share.
| Cash & Cash Equivalents | 15.12M |
| Total Debt | 106.25M |
| Net Cash | -91.13M |
| Net Cash Per Share | -$1.44 |
| Equity (Book Value) | -103.07M |
| Book Value Per Share | -1.67 |
| Working Capital | -18.16M |
Full Balance SheetCash Flow
| Operating Cash Flow | -41.77M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |